Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
about
Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to BoneNovel agents in the treatment of multiple myeloma: a review about the futureActivation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.In vivo immune signatures of healthy human pregnancy: Inherently inflammatory or anti-inflammatory?Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.Plasma cells: finding new light at the end of B cell development.Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.Effects of all-trans retinoic acid (ATRA) on human myeloma cells.Interleukin-6 is an autocrine growth factor in human prostate cancer.Targeting signalling pathways for the treatment of multiple myeloma.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?4-Hydroxy-2,3-Dimethyl-2-Nonen-4-Olide Has an Inhibitory Effect on Pro-Inflammatory Cytokine Production in CpG-Stimulated Bone Marrow-Derived Dendritic Cells.Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cellsApo-9'-fucoxanthinone, isolated from Sargassum muticum, inhibits CpG-induced inflammatory response by attenuating the mitogen-activated protein kinase pathway.CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation.New approaches to divorce with children: A problem of public health.Adipocyte-derived players in hematologic tumors: useful novel targets?Massive plasmacytosis with severe marrow suppression induced by methimazole in Graves' disease patients: case report and literature review.IκBε is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner.Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression.The immunoproteasome: An old player with a novel and emerging role in alloimmunity.MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.Toll-like receptors mediate proliferation and survival of multiple myeloma cells.Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer.Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage.Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.Monoolein, isolated from , inhibits lipopolysaccharide-induced inflammatory response by attenuating mitogen-activated protein kinase and NF-κB pathways
P2860
Q26740710-7FB51E82-AE6A-4133-A6EE-4E852215E188Q26745924-598B3CA3-E8F3-4959-8F1D-6D275A5D4261Q28204011-C55C078E-C0E9-4396-A7C5-0DA60FF901A8Q33685257-F052563C-50A0-4949-96FC-F806FB6FBD34Q33821861-AA862A87-E046-443D-89DC-39AF8BDA88F2Q34420112-B0EFED2C-0D7D-4ADD-A3AB-35FF6F0CB12BQ34450168-7E5E166B-4377-4E55-B403-3477FE6B277AQ34502870-679DB493-549B-4622-96FF-6749B8E4B3F4Q35614620-DF6597EA-3A15-4289-BE8F-E59AFC3CC275Q35747214-D556E176-FC1E-4565-B8FC-0F0641F09A5DQ36150866-511BEDBF-CE9D-4A94-A7C2-7881425619DDQ36289608-B86F165C-F695-4EC5-9CBC-3C166CE0F689Q36941460-3A3EEC4C-5299-4203-8F6F-84544AD10E21Q37161467-BC7E8100-57DC-4409-BC48-5DC75C97139DQ37250742-5C634BB7-A3D8-4C89-B0EC-79FA4BD05997Q37483026-3141F363-79D2-4DC2-B0B7-14104EE231CBQ37540595-51E0C826-A1A5-4361-91DC-AC8656E8A0E1Q38259527-07B8EDE1-9CF2-450B-BF1D-E674713D56E7Q38270816-B496401F-9319-4136-91F9-9B12FCE05BADQ38508131-088F4D63-30A2-49A7-82B9-B8DFE1EA46FBQ39427003-30613F08-054D-4B05-98F1-104ADE918A79Q39441681-E8BD3BC3-7EE4-4F7F-86F9-DCCCFB842C32Q39908262-E0FAE749-902B-40D9-8D0D-E0017A892896Q40291993-244D27A8-038E-40F3-B7B3-07B0F1AD6AA7Q40359356-B277BA37-4442-4DC3-A79F-152E8698E82BQ40644713-2FE61263-16D1-4A66-A15C-22C8FDAF0F88Q41369617-1013B5B0-15AA-4D37-A3DF-4B7415C59591Q55035844-0A0EC410-D2F9-4515-95F9-BEEFD82DA8DBQ55086372-7892D27F-36DA-4A7C-975A-2EAEE30DDA36Q57212209-B5D23F8F-F2FA-447A-A2A2-F1DB779B9C98
P2860
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@ast
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@en
type
label
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@ast
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@en
prefLabel
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@ast
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@en
P2093
P356
P1476
Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
@en
P2093
P304
P356
10.1006/CBIR.2000.0497
P577
2000-01-01T00:00:00Z